Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ambrx
Biotech
J&J sees ‘opportunities’ in neuro and immunology post-Ambrx buy
J&J execs reiterated they are agnostic to sector and size when it comes to deals, but that they prefer to stay in already carved-out lanes.
Max Bayer
Jan 23, 2024 10:54am
J&J beefs up ADC pipeline by acquiring Ambrx for $2B
Jan 8, 2024 8:25am
Ambrx's 'reset' arrives at the last line of prostate cancer
Oct 22, 2023 9:39am
FDA's Peter Marks doesn't plan to retire soon—Chutes & Ladders
Aug 4, 2023 9:30am
New Ambrx CEO spies a path for ousted breast cancer med
Mar 1, 2023 11:20am
New federal biotech commission taps 12 members—Chutes & Ladders
Feb 3, 2023 10:20am